Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:    
License and other revenues
Expenses:    
Research and development 7,207 8,041
General and administrative 7,123 3,997
Total expenses 14,330 12,038
Loss from operations (14,330) (12,038)
Interest income 843 364
Interest expense (952) (101)
Change in fair value of warrant and derivative liabilities (17,301) 2,265
Other income 162 403
Net loss $ (31,578) $ (9,107)
Loss per common share - basic $ (1.16) $ (0.54)
Loss per common share - diluted $ (1.16) $ (0.54)
Weighted average number of common shares outstanding - basic 27,315,537 16,904,024
Weighted average number of common shares outstanding - diluted 27,315,537 16,904,024
Other comprehensive income (loss):    
Change in unrealized (losses) gains related to available-for-sale debt securities $ (118) $ 64
Comprehensive loss $ (31,696) $ (9,043)